The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
Location status: Recruiting
Recruiting
NCT Number: NCT07066813
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:
* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
- Patients who have undergone surgical lung resection;
- Patients with complete preoperative chest CT imaging data;
- Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.
Exclusion criteria
- History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis [LAM], or Birt-Hogg-Dubé [BHD] syndrome);
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Patients with concurrent other malignancies;
- Patients with missing or poor-quality preoperative chest CT imaging data.
Treatment and study plan
Primary outcomes
-
DFS
Time frame: From enrollment to the end of surgery for 5 years
Disease-Free Survival
-
OS
Time frame: From enrollment to the end of surgery for 5 years
Overall Survival
Secondary outcomes
-
Rate of T-stage reclassification
Time frame: From enrollment to the end of surgery for 5 years
T-stage reclassification
-
AI-based extraction of radiologic characteristics of cystic airspace-associated lesions
Time frame: From enrollment to the end of surgery for 5 years
Machine learning was employed to extract and analyze the radiologic characteristics of cystic airspace-associated lesions.
-
AI to extract and analyze pathological features
Time frame: From enrollment to the end of surgery for 5 years
Machine learning was employed to extract and analyze pathological features
-
Oncogenic driver genetic alterations
Time frame: From enrollment to the end of surgery for 5 years
Results of driver gene mutation testing
-
Receipt of postoperative adjuvant therapy
Time frame: From enrollment to the end of surgery for 5 years
Postoperative adjuvant therapy was ascertained from medical records
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Central South University
Other
Registry information
Official study title
T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Jul 15, 2025
- Registry last updated
- Jul 8, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979
Bronchial Neoplasms, Carcinoma, Bronchogenic
Changsha, Hunan, China
View Trial Details